Inhibitory effect of Carthamus tinctorius L. seed extracts on bone resorption mediated by tyrosine kinase, COX-2 (cyclooxygenase) and PG (prostaglandin) E2.
Anti-bone resorption properties of the Korean herbal formulation, Honghwain (HHI; Carthamus tinctorius L. seed) was biochemically investigated. On processing bone metabolism, PGE2 accelerated production of IL-1beta in fetal mouse osteoblast and stimulated physiological activation substance, IL-1beta. The novel class of Src tyrosine kinase inhibitors, Herbimycin A (HERB) and HHI reduced COX-2 mRNA levels as well as PGE2 production induced by IL-1beta, TNF-alpha and IL-6. HHI inhibited in vitro and in vivo bone resorption by inhibition of phosphorylation of peptide substrates. HHI dose-dependently reduced the hypercalcemia induced in mice by IL-1beta and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption. These results indicate that the synergy between IL-beta, TNF-alpha, IL-6 on PGE2 production is due to an enhanced gene expression of COX-2 and that tyrosine kinase (s) are involved in the signal transduction of COX-2 in mouse calvarial osteoblasts. Thus, HHI as a possible Src family kinase inhibitor may be useful for the treatment of diseases associated with elevated bone loss.
Yuk
Tae Han
TH
Department of Acupuncture and Moxibustion, College of Oriental Medicine, Woosuk University, Chonbuk, Korea.
Kang
Joon Hyeog
JH
Lee
Sang Ryoung
SR
Yuk
Sang Won
SW
Lee
Kwang Gyu
KG
Song
Beum Yong
BY
Kim
Cheorl Ho
CH
Kim
Dong Wook
DW
Dong
Il Kim
IK
Lee
Tae Kyun
TK
Lee
Chang Hyun
CH
D000818:Animals; D016227:Benzoquinones; D001862:Bone Resorption / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D001842:Bone and Bones / Q000473:pathology; D031178:Carthamus / Q000737:chemistry*; D002469:Cell Separation; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D016207:Cytokines / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology*; D005260:Female; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy; D007527:Isoenzymes / Q000096:biosynthesis / Q000378:metabolism*; D047029:Lactams, Macrocyclic; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000037:antagonists & inhibitors / Q000633:toxicity; D010936:Plant Extracts / Q000494:pharmacology*; D011448:Prostaglandin Antagonists / Q000494:pharmacology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011809:Quinones / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D017828:Rifabutin / Q000031:analogs & derivatives; D012639:Seeds / Q000737:chemistry
D016227:Benzoquinones; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D007527:Isoenzymes; D047029:Lactams, Macrocyclic; D008565:Membrane Proteins; D010281:Parathyroid Hormone; D010936:Plant Extracts; D011448:Prostaglandin Antagonists; D011809:Quinones; D012333:RNA, Messenger; D017828:Rifabutin; C020754:herbimycin; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C496512:Ptgs1 protein, mouse; D011505:Protein-Tyrosine Kinases; D015232:Dinoprostone